U.S. Markets open in 3 hrs 28 mins
  • Gold

    1,788.50
    +3.60 (+0.20%)
     
  • EUR/USD

    1.1644
    -0.0008 (-0.0699%)
     
  • 10-Yr Bond

    1.6360
    0.0000 (0.00%)
     
  • Vix

    16.00
    +0.30 (+1.91%)
     
  • GBP/USD

    1.3801
    -0.0025 (-0.1808%)
     
  • USD/JPY

    114.0610
    -0.2680 (-0.2344%)
     
  • BTC-USD

    66,222.39
    +2,200.68 (+3.44%)
     
  • CMC Crypto 200

    1,566.02
    +85.22 (+5.75%)
     
  • FTSE 100

    7,201.25
    -21.85 (-0.30%)
     
  • Nikkei 225

    28,708.58
    -546.97 (-1.87%)
     

BioNTech Prepares To Launch COVID-19 Shot For 5 to11 Year Old: Reuters

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • BioNTech SE (NASDAQ: BNTX) is reportedly prepping a launch for its mRNA-based COVID-19 vaccine developed with Pfizer Inc (NYSE: PFE) for children between 5 and 11 years old.

  • Also read: Pfizer/BioNTech Initiates COVID-19 Vaccine Trial In Children Below 12 Years.

  • BioNTech CMO Özlem Türeci told the weekly German magazine, Der Spiegel, that the Company would file the results of its trial in 5- to 11-year-olds with regulators across the world "over the next few weeks," reported Reuters.

  • The Company also said that the final production steps are being adjusted to bottle a lower-dose pediatric vaccine version.

  • "Things are looking good, everything is going according to plan," CEO Ugur Sahin told Der Spiegel.

  • The Pfizer/BioNTech vaccine is currently authorized for children as young as 12 years old, and back in August became the first COVID-19 vaccine to secure full FDA approval for people 16 years and older.

  • Related Content: FDA Schedules Adcomm For Pfizer/BioNTech's COVID-19 Booster Shot.

  • European Medicines Agency and CDC backed the use of Pfizer-BioNTech COVID-19 Vaccine For 12-15 Age Group.

  • Moderna Inc (NASDAQ: MRNA) began recruiting in March to test the mRNA jab in kids younger than 12 years.

  • In July New York Times reported that Pfizer, BioNTech, and Moderna would expand vaccine trials in children ages five to 11.

  • Price Action: PFE stock is down 0.89% at $45.63, BNTX stock is up 0.93% at $354.64 during the market session on the last check Friday.

  • Photo by x3 from Pixabay

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.